Cowen Reiterates Outperform Rating on Allogene (ALLO), "We Recommend Accumulating ALLO Shares"

Cowen analyst Tyler Van Buren reiterated an Outperform rating on Allogene (NASDAQ: ALLO), following resumption of the company's AlloCAR T studies.

The analyst quotes: "All AlloCAR T studies have resumed and Allogene has plenty of cash ($810MM). The pivotal ALPHA2 ALLO-501A trial is on track to commence mid-year with a registrational ALLO-647 trial that will be conducted in parallel and should be informative. Clinical study activities for ALLO-715, ALLO-605, and ALLO-316 have also resumed with a BCMA update expected by YE. We recommend accumulating ALLO shares."

For an analyst ratings summary and ratings history on Allogene click here. For more ratings news on Allogene click here.

Shares of Allogene closed at $9.17 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In

• Walmart (WMT) started at Overweight at Barclays on defensive characteristics
• TFI International Inc. (TFII:CN) (TFII) PT Raised to Cdn$185 at TD Securities
• Orion Corp. (271560:KS) PT Raised to KRW142,000 at Goldman Sachs